Skip to main content
Back
Watch Compare

Protara Therapeutics, Inc.

Data quality: 83%
TARA
Nasdaq Manufacturing Chemicals
$4.96
▼ $0.35 (-6.59%)
Mkt Cap: 285.02 M
Price
$5.27
Mkt Cap
285.02 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -56.46 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-41.52%
Above sector avg (-53.47%)
ROIC-36.18%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio13.69
Interest CoverageN/A

Valuation

PE (TTM)
-4.96
Below sector avg (-1.48)
P/B Ratio2.15
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -5.0 -1.5
P/B 2.2 1.6
ROE % -41.5 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

7 analysts
Buy
Current
$4.96
+418.4%
Target
$25.71
$23.00
$25.00
$30.00
Forecast
Forward P/E -3.57
Forward EPS -$1.39
Est. Revenue 21.71 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$1.39
-$2.01 – -$0.40
 21.71 M 7
FY2026 -$1.54
-$1.74 – -$1.31
 0.0 6

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.31 -$0.38 -21.8%
Q32025 -$0.39 -$0.31 +19.5%
Q22025 -$0.41 -$0.35 +15.3%
Q12025 -$0.48 -$0.29 +39.3%

ETFs Holding This Stock

BRSIX BRSIX
0.17% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.01% weight
AVSCX AVSCX
0.01% weight
VVICX VVICX
0.01% weight
IIRSX IIRSX
0.01% weight
IRSIX IRSIX
0.01% weight
IRCIX IRCIX
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -57.44 M
ROE -41.52% ROA -38.09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -56.46 M
ROIC -36.18% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 13.69
Interest Coverage N/A Asset Turnover N/A
Working Capital 125.74 M Tangible Book Value 132.29 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.96 Forward P/E N/A
P/B Ratio 2.15 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19.81%
Market Cap 285.02 M Enterprise Value 272.47 M
Per Share
EPS (Diluted TTM) -1.34 Revenue / Share N/A
FCF / Share -1.04 OCF / Share -1.04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98.29%
SBC-Adj. FCF -60.17 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -57.44 M -44.60 M -40.42 M -65.95 M -47.25 M
EPS (Diluted) -1.34 -2.17 -3.57 -5.86 —
Gross Profit — — — — —
Operating Income -64.55 M -49.15 M -43.61 M -67.06 M -47.49 M
EBITDA — — — — —
R&D Expenses 42.63 M 31.70 M 24.99 M 16.81 M 21.09 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — 0.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 209.47 M 181.45 M 78.95 M 113.29 M 172.60 M
Total Liabilities 13.06 M 14.32 M 10.63 M 11.21 M 10.68 M
Shareholders' Equity 196.41 M 167.13 M 68.32 M 102.08 M 161.91 M
Total Debt — — — — —
Cash & Equivalents 49.66 M 162.80 M 39.59 M 24.13 M 35.72 M
Current Assets 159.50 M 172.16 M 68.71 M 86.15 M 93.11 M
Current Liabilities 10.94 M 10.96 M 6.15 M 5.74 M 4.30 M